Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
42
MNOV Quote, Financials, Valuation and Earnings
Last price:
$1.57
Seasonality move
:
11.21%
Day range:
$1.55 - $1.59
52-week range:
$1.13 - $1.96
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
294.77x
P/B ratio:
1.73x
Volume:
40.7K
Avg. volume:
80.2K
1-year change:
-21.32%
Market cap:
$76.2M
Revenue:
--
EPS (TTM):
-$0.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MNOV
MediciNova, Inc.
|
-- | -$0.10 | -100% | -65.51% | $10.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$24.3M | -$0.15 | -- | -45.37% | $9.67 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835.1M | $0.59 | 11.8% | 33.07% | $88.87 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MNOV
MediciNova, Inc.
|
$1.55 | $10.00 | $76.2M | -- | $0.00 | 0% | 294.77x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.33 | $31.21 | $4.1B | 15.65x | $0.00 | 0% | 3.91x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$5.08 | $9.67 | $305.6M | -- | $0.00 | 0% | -- |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$339.37 | $457.00 | $45B | 150.36x | $0.00 | 0% | 12.20x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$63.42 | $88.87 | $12.2B | 23.76x | $0.00 | 0% | 4.02x |
|
SVRA
Savara, Inc.
|
$5.72 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MNOV
MediciNova, Inc.
|
0.58% | 0.950 | 0.41% | 9.76x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 2.196 | 4.95% | 2.64x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MNOV
MediciNova, Inc.
|
-$39K | -$3.4M | -24.01% | -24.18% | -2742.09% | -$1.7M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
MediciNova, Inc. vs. Competitors
-
Which has Higher Returns MNOV or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -2473.97% compared to MediciNova, Inc.'s net margin of 25.76%. MediciNova, Inc.'s return on equity of -24.18% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital MNOVMediciNova, Inc.-31.63% -$0.06 $44.2M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About MNOV or ACAD?
MediciNova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 545.16%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 28.28%. Given that MediciNova, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe MediciNova, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNOVMediciNova, Inc.2 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is MNOV or ACAD More Risky?
MediciNova, Inc. has a beta of 0.548, which suggesting that the stock is 45.242% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock MNOV or ACAD?
MediciNova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MNOV or ACAD?
MediciNova, Inc. quarterly revenues are $123.3K, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. MediciNova, Inc.'s net income of -$3.1M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, MediciNova, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova, Inc. is 294.77x versus 3.91x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNOVMediciNova, Inc.294.77x -- $123.3K -$3.1M ACADACADIA Pharmaceuticals, Inc.3.91x 15.65x $278.6M $71.8M
-
Which has Higher Returns MNOV or ALDX?
Aldeyra Therapeutics, Inc. has a net margin of -2473.97% compared to MediciNova, Inc.'s net margin of --. MediciNova, Inc.'s return on equity of -24.18% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.
Company Gross Margin Earnings Per Share Invested Capital MNOVMediciNova, Inc.-31.63% -$0.06 $44.2M ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M -
What do Analysts Say About MNOV or ALDX?
MediciNova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 545.16%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 90.29%. Given that MediciNova, Inc. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe MediciNova, Inc. is more attractive than Aldeyra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNOVMediciNova, Inc.2 0 0 ALDXAldeyra Therapeutics, Inc.4 0 0 -
Is MNOV or ALDX More Risky?
MediciNova, Inc. has a beta of 0.548, which suggesting that the stock is 45.242% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.984, suggesting its less volatile than the S&P 500 by 1.635%.
-
Which is a Better Dividend Stock MNOV or ALDX?
MediciNova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MNOV or ALDX?
MediciNova, Inc. quarterly revenues are $123.3K, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. MediciNova, Inc.'s net income of -$3.1M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, MediciNova, Inc.'s price-to-earnings ratio is -- while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova, Inc. is 294.77x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNOVMediciNova, Inc.294.77x -- $123.3K -$3.1M ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M
-
Which has Higher Returns MNOV or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -2473.97% compared to MediciNova, Inc.'s net margin of 16.99%. MediciNova, Inc.'s return on equity of -24.18% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital MNOVMediciNova, Inc.-31.63% -$0.06 $44.2M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About MNOV or ALNY?
MediciNova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 545.16%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 34.66%. Given that MediciNova, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe MediciNova, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNOVMediciNova, Inc.2 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is MNOV or ALNY More Risky?
MediciNova, Inc. has a beta of 0.548, which suggesting that the stock is 45.242% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock MNOV or ALNY?
MediciNova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MNOV or ALNY?
MediciNova, Inc. quarterly revenues are $123.3K, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. MediciNova, Inc.'s net income of -$3.1M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, MediciNova, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 150.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova, Inc. is 294.77x versus 12.20x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNOVMediciNova, Inc.294.77x -- $123.3K -$3.1M ALNYAlnylam Pharmaceuticals, Inc.12.20x 150.36x $1.1B $186.4M
-
Which has Higher Returns MNOV or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -2473.97% compared to MediciNova, Inc.'s net margin of -3.91%. MediciNova, Inc.'s return on equity of -24.18% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital MNOVMediciNova, Inc.-31.63% -$0.06 $44.2M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About MNOV or BMRN?
MediciNova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 545.16%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 40.13%. Given that MediciNova, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe MediciNova, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNOVMediciNova, Inc.2 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is MNOV or BMRN More Risky?
MediciNova, Inc. has a beta of 0.548, which suggesting that the stock is 45.242% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock MNOV or BMRN?
MediciNova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MNOV or BMRN?
MediciNova, Inc. quarterly revenues are $123.3K, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. MediciNova, Inc.'s net income of -$3.1M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, MediciNova, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 23.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova, Inc. is 294.77x versus 4.02x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNOVMediciNova, Inc.294.77x -- $123.3K -$3.1M BMRNBioMarin Pharmaceutical, Inc.4.02x 23.76x $786.8M -$30.7M
-
Which has Higher Returns MNOV or SVRA?
Savara, Inc. has a net margin of -2473.97% compared to MediciNova, Inc.'s net margin of --. MediciNova, Inc.'s return on equity of -24.18% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital MNOVMediciNova, Inc.-31.63% -$0.06 $44.2M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About MNOV or SVRA?
MediciNova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 545.16%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 89.03%. Given that MediciNova, Inc. has higher upside potential than Savara, Inc., analysts believe MediciNova, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNOVMediciNova, Inc.2 0 0 SVRASavara, Inc.6 0 0 -
Is MNOV or SVRA More Risky?
MediciNova, Inc. has a beta of 0.548, which suggesting that the stock is 45.242% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock MNOV or SVRA?
MediciNova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MNOV or SVRA?
MediciNova, Inc. quarterly revenues are $123.3K, which are larger than Savara, Inc. quarterly revenues of --. MediciNova, Inc.'s net income of -$3.1M is higher than Savara, Inc.'s net income of -$29.6M. Notably, MediciNova, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova, Inc. is 294.77x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNOVMediciNova, Inc.294.77x -- $123.3K -$3.1M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 21.87% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 16.79% over the past day.
